The effects of mometasone furoate and desloratadine in obstructive sleep apnea syndrome patients with allergic rhinitis

dc.authorid0000-0003-2744-2266
dc.authorid0000-0002-3875-2318
dc.authorid0000-0002-1553-2902
dc.contributor.authorAcar, Mustafa
dc.contributor.authorCingi, Cemal
dc.contributor.authorSakallioglu, Oner
dc.contributor.authorSan, Turhan
dc.contributor.authorYimenicioglu, Mehmet Fatih
dc.contributor.authorBal, Cengiz
dc.date.accessioned2025-05-10T19:36:00Z
dc.date.issued2013
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractBackground: Allergic rhinitis (AR) and obstructive sleep apnea syndrome (OSAS) are worldwide prevalent diseases. These diseases impair patient quality of life. The aim of this study was to investigate and compare the efficacy of treatment of AR on OSAS by objective and subjective methods. Methods: The study group was composed of 80 OSAS patients with AR between the ages of 30 and50 years. The patients were admitted with the complaint of snoring, and they were asked about AR-related symptoms (nasal discharge, nasal itching, sneeze, and nasal obstruction). Daytime somnolence was measured by the Epworth sleepiness scale (ESS). Sleep parameters on polysomnography tests before and after treatment were compared, and the effects of different AR treatment protocols on sleep quality were evaluated. Results: When pretreatment and posttreatment apnea-hypopnea index (AHI) values of the groups were compared, the most significant difference was observed in the nasal steroid (Ns) + antihistamine (Ah) group (p < 0.05). The ESS results were significantly decreased in the Ns and Ns + Ah groups after treatment (p < 0.05). AHI oxygen saturation <90% were significantly decreased in the Ns and Ns + Ah groups after treatment (p < 0.05). Conclusion: Nasal obstruction due to nasal congestion causes increases in airway resistance and can lead to development of OSAS. We concluded that treating AR with Ns has both positive effects on OSAS and daily activity. However, adding Ah to this treatment did not show improved effects compared with placebo treatment.
dc.identifier.doi10.2500/ajra.2013.27.3921
dc.identifier.endpageE116
dc.identifier.issn1945-8924
dc.identifier.issn1945-8932
dc.identifier.issue4
dc.identifier.pmid23883803
dc.identifier.scopus2-s2.0-84883371597
dc.identifier.scopusqualityQ1
dc.identifier.startpageE113
dc.identifier.urihttps://doi.org/10.2500/ajra.2013.27.3921
dc.identifier.urihttps://hdl.handle.net/20.500.14730/9041
dc.identifier.volume27
dc.identifier.wosWOS:000322549600007
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSage Publications Inc
dc.relation.ispartofAmerican Journal of Rhinology & Allergy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectQuality-Of-Life
dc.subjectRisk-Factor
dc.subjectNasal Congestion
dc.subjectSymptoms
dc.subjectImpairment
dc.subjectTherapy
dc.subjectSurgery
dc.subjectSpray
dc.titleThe effects of mometasone furoate and desloratadine in obstructive sleep apnea syndrome patients with allergic rhinitis
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
9041.pdf
Boyut:
84.99 KB
Biçim:
Adobe Portable Document Format